Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, Cecilia Kiilu, Moses Chitsamatanga, Tiyara Arumugam, Alexandra Green, Cissy Kityo Mutuluuza, Mutsa Bwakura-Dangarembizi, Abraham Siika, Moherndran Archary, Lungile Jafta, Stella Namukwaya, Janet Seeley, George Patrick Akabwai, Henry Mugerwa, Lisanne A. H. Bevers, David Burger, Simon Walker, Alasdair Bamford, Annabelle South, Naomi Apoto, Molly Bush, Margaret J Thomason, Ben Spittle, Deborah Ford, Adeodata R Kekitiinwa, Sarah Pett, LATA Trial Team